Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Apollomics Inc. - Class A Ordinary Shares (APLM)
Company Research
Source: GlobeNewswire
FOSTER CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced poster presentations on vebreltinib (APL-101) at the 2024 American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, Calif. Copies of the posters will be made available on the Apollomics website following the presentation at ir.apollomicsinc.com/news-events/presentations. Poster Presentation Details Title:Vebreltinib: A novel brain-penetrating MET kinase inhibitor demonstrates the mechanism of action and pharmacological anti-tumor activity in diverse patient-derived MET-dysregulated tumor models at clinically relevant drug levelsSession Category:Experimental and Molecular Therapeutics, Molecular/Cellular Biology and GeneticsSession Title: Kinase and Phosphatase Inhibitors 1Section #:25Date and Time:April 7, 2
Show less
Read more
Impact Snapshot
Event Time:
APLM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APLM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APLM alerts
High impacting Apollomics Inc. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
APLM
News
- Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Apollomics Announces Presentation at the 2024 BIO International ConventionGlobeNewswire
- Apollomics Announces Private Placement Financing and Addition to Board of DirectorsGlobeNewswire
- Apollomics, Inc. (NASDAQ: APLM) had its price target lowered by analysts at HC Wainwright from $5.00 to $2.00. They now have a "buy" rating on the stock.MarketBeat
APLM
Sec Filings
- 5/30/24 - Form SC
- 5/30/24 - Form EFFECT
- 5/29/24 - Form 424B3
- APLM's page on the SEC website